Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
Jason Pharmaceuticals, Inc. a subsidiary of Medifast, Inc. (NYSE: MED), a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today announced that it has reached a proposed consent agreement with the Federal Trade Commission ("FTC"), resolving the FTC's non-public investigation of certain statements in the Company's advertising for its weight-loss programs.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.